| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bipolar Disorder | 31 | 2021 | 246 | 3.940 |
Why?
|
| Infant, Extremely Premature | 23 | 2025 | 38 | 3.100 |
Why?
|
| Child | 126 | 2025 | 4541 | 2.800 |
Why?
|
| Antipsychotic Agents | 18 | 2022 | 301 | 2.650 |
Why?
|
| Psychotic Disorders | 14 | 2022 | 158 | 2.610 |
Why?
|
| Mental Disorders | 17 | 2025 | 795 | 2.440 |
Why?
|
| Autism Spectrum Disorder | 12 | 2023 | 179 | 2.430 |
Why?
|
| Adolescent | 107 | 2025 | 6260 | 2.140 |
Why?
|
| Schizophrenia, Childhood | 19 | 2018 | 21 | 2.120 |
Why?
|
| Schizophrenia | 19 | 2022 | 263 | 1.970 |
Why?
|
| Magnetic Resonance Imaging | 27 | 2022 | 2188 | 1.690 |
Why?
|
| Autistic Disorder | 8 | 2023 | 146 | 1.610 |
Why?
|
| Intellectual Disability | 4 | 2024 | 168 | 1.610 |
Why?
|
| Child Development Disorders, Pervasive | 8 | 2021 | 44 | 1.520 |
Why?
|
| Brain | 23 | 2022 | 1556 | 1.450 |
Why?
|
| Schizophrenic Psychology | 14 | 2018 | 66 | 1.420 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 14 | 2022 | 158 | 1.290 |
Why?
|
| Humans | 166 | 2025 | 63577 | 1.210 |
Why?
|
| Emotions | 4 | 2023 | 223 | 1.110 |
Why?
|
| Cognition | 12 | 2023 | 484 | 1.110 |
Why?
|
| Infant, Newborn | 26 | 2025 | 1363 | 1.070 |
Why?
|
| Risperidone | 7 | 2012 | 25 | 0.980 |
Why?
|
| Child Psychiatry | 6 | 2020 | 40 | 0.960 |
Why?
|
| Mood Disorders | 6 | 2009 | 72 | 0.930 |
Why?
|
| Mental Health | 7 | 2025 | 371 | 0.920 |
Why?
|
| Male | 102 | 2025 | 29957 | 0.900 |
Why?
|
| Anxiety Disorders | 6 | 2023 | 192 | 0.890 |
Why?
|
| Female | 106 | 2025 | 32973 | 0.880 |
Why?
|
| Neuropsychological Tests | 12 | 2018 | 393 | 0.850 |
Why?
|
| Comorbidity | 13 | 2024 | 1117 | 0.820 |
Why?
|
| Antimanic Agents | 7 | 2017 | 31 | 0.820 |
Why?
|
| Limbic System | 3 | 2009 | 27 | 0.810 |
Why?
|
| Developmental Disabilities | 5 | 2022 | 116 | 0.810 |
Why?
|
| Child Abuse | 3 | 2020 | 88 | 0.810 |
Why?
|
| Child Development | 5 | 2022 | 84 | 0.770 |
Why?
|
| Depressive Disorder, Major | 4 | 2021 | 248 | 0.770 |
Why?
|
| Cognition Disorders | 7 | 2018 | 217 | 0.770 |
Why?
|
| Gyrus Cinguli | 5 | 2015 | 57 | 0.750 |
Why?
|
| Child Behavior Disorders | 3 | 2021 | 38 | 0.740 |
Why?
|
| Self-Injurious Behavior | 1 | 2022 | 48 | 0.740 |
Why?
|
| Psychiatric Status Rating Scales | 28 | 2022 | 390 | 0.730 |
Why?
|
| Lithium Carbonate | 7 | 2017 | 12 | 0.720 |
Why?
|
| Mental Health Services | 2 | 2024 | 289 | 0.720 |
Why?
|
| Editorial Policies | 5 | 2023 | 55 | 0.710 |
Why?
|
| Neurodevelopmental Disorders | 6 | 2025 | 41 | 0.710 |
Why?
|
| Child, Preschool | 26 | 2022 | 1999 | 0.660 |
Why?
|
| Interpersonal Relations | 2 | 2019 | 152 | 0.650 |
Why?
|
| Age of Onset | 21 | 2014 | 174 | 0.630 |
Why?
|
| Neuroimaging | 4 | 2020 | 153 | 0.630 |
Why?
|
| Health Services Accessibility | 1 | 2024 | 566 | 0.620 |
Why?
|
| Basal Ganglia | 4 | 2013 | 34 | 0.620 |
Why?
|
| Gestational Age | 10 | 2025 | 191 | 0.610 |
Why?
|
| Alpha Rhythm | 1 | 2019 | 3 | 0.610 |
Why?
|
| Neurobiology | 2 | 2009 | 5 | 0.600 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 2014 | 398 | 0.600 |
Why?
|
| Electroencephalography | 3 | 2021 | 150 | 0.590 |
Why?
|
| Infant, Premature, Diseases | 3 | 2025 | 47 | 0.580 |
Why?
|
| Clozapine | 9 | 2007 | 32 | 0.580 |
Why?
|
| Benzodiazepines | 6 | 2012 | 100 | 0.570 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 7 | 2021 | 119 | 0.560 |
Why?
|
| Publishing | 4 | 2020 | 92 | 0.560 |
Why?
|
| Siblings | 1 | 2018 | 43 | 0.560 |
Why?
|
| Molindone | 4 | 2012 | 7 | 0.550 |
Why?
|
| Psychotropic Drugs | 5 | 2022 | 84 | 0.540 |
Why?
|
| gamma-Aminobutyric Acid | 3 | 2015 | 76 | 0.540 |
Why?
|
| Biomedical Research | 5 | 2022 | 269 | 0.530 |
Why?
|
| Cooperative Behavior | 1 | 2019 | 223 | 0.530 |
Why?
|
| Pediatrics | 3 | 2018 | 257 | 0.520 |
Why?
|
| Glutamine | 2 | 2015 | 48 | 0.510 |
Why?
|
| Epilepsy | 5 | 2021 | 111 | 0.500 |
Why?
|
| Anxiety | 8 | 2025 | 429 | 0.490 |
Why?
|
| Cerebral Palsy | 3 | 2021 | 18 | 0.470 |
Why?
|
| Attention Deficit and Disruptive Behavior Disorders | 2 | 2014 | 18 | 0.470 |
Why?
|
| Biofeedback, Psychology | 2 | 2005 | 6 | 0.460 |
Why?
|
| Adult | 34 | 2024 | 16899 | 0.460 |
Why?
|
| Adolescent Psychiatry | 3 | 2020 | 18 | 0.460 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2015 | 74 | 0.450 |
Why?
|
| Information Dissemination | 2 | 2015 | 116 | 0.450 |
Why?
|
| Vagus Nerve | 2 | 2005 | 21 | 0.450 |
Why?
|
| Cognitive Dysfunction | 5 | 2020 | 332 | 0.450 |
Why?
|
| Electric Stimulation Therapy | 2 | 2005 | 27 | 0.450 |
Why?
|
| Magnetics | 2 | 2005 | 53 | 0.440 |
Why?
|
| Brain Mapping | 8 | 2012 | 232 | 0.440 |
Why?
|
| United States | 22 | 2025 | 7854 | 0.440 |
Why?
|
| Cohort Studies | 16 | 2024 | 2575 | 0.440 |
Why?
|
| Irritable Mood | 1 | 2014 | 16 | 0.430 |
Why?
|
| Quinolones | 1 | 2014 | 29 | 0.430 |
Why?
|
| White Matter | 1 | 2015 | 123 | 0.420 |
Why?
|
| Pregnancy | 13 | 2023 | 2335 | 0.420 |
Why?
|
| Pandemics | 4 | 2024 | 670 | 0.420 |
Why?
|
| Piperazines | 1 | 2014 | 81 | 0.420 |
Why?
|
| Emotional Intelligence | 1 | 2013 | 4 | 0.420 |
Why?
|
| Weight Gain | 4 | 2011 | 168 | 0.420 |
Why?
|
| Adult Survivors of Child Abuse | 1 | 2013 | 13 | 0.410 |
Why?
|
| Achievement | 4 | 2021 | 29 | 0.400 |
Why?
|
| Prenatal Exposure Delayed Effects | 4 | 2021 | 156 | 0.400 |
Why?
|
| Oxytocin | 1 | 2013 | 45 | 0.400 |
Why?
|
| Prospective Studies | 15 | 2025 | 3302 | 0.400 |
Why?
|
| Life Change Events | 1 | 2013 | 66 | 0.400 |
Why?
|
| Infant | 9 | 2022 | 1654 | 0.400 |
Why?
|
| Quality of Life | 4 | 2025 | 1241 | 0.390 |
Why?
|
| Severity of Illness Index | 17 | 2025 | 1556 | 0.390 |
Why?
|
| Young Adult | 17 | 2022 | 4717 | 0.390 |
Why?
|
| Reproducibility of Results | 8 | 2023 | 1666 | 0.390 |
Why?
|
| Child Health | 4 | 2022 | 31 | 0.380 |
Why?
|
| Fragile X Syndrome | 2 | 2022 | 27 | 0.370 |
Why?
|
| Tryptamines | 3 | 2016 | 13 | 0.370 |
Why?
|
| Corpus Callosum | 1 | 2010 | 42 | 0.340 |
Why?
|
| Aging | 6 | 2019 | 745 | 0.340 |
Why?
|
| Follow-Up Studies | 12 | 2025 | 2464 | 0.330 |
Why?
|
| Cerebral Cortex | 6 | 2015 | 263 | 0.320 |
Why?
|
| Risk | 3 | 2018 | 378 | 0.320 |
Why?
|
| Intelligence | 3 | 2022 | 52 | 0.320 |
Why?
|
| Sex Factors | 10 | 2018 | 974 | 0.310 |
Why?
|
| Retinopathy of Prematurity | 2 | 2025 | 14 | 0.290 |
Why?
|
| Age Factors | 12 | 2021 | 1565 | 0.290 |
Why?
|
| Social Environment | 2 | 2025 | 93 | 0.280 |
Why?
|
| Metformin | 1 | 2009 | 74 | 0.280 |
Why?
|
| Neuroglia | 2 | 2007 | 79 | 0.280 |
Why?
|
| Thalamus | 3 | 2010 | 73 | 0.270 |
Why?
|
| Longitudinal Studies | 4 | 2025 | 1259 | 0.270 |
Why?
|
| Migraine Disorders | 3 | 2016 | 41 | 0.270 |
Why?
|
| Lithium Compounds | 2 | 2018 | 8 | 0.270 |
Why?
|
| Health Services Needs and Demand | 2 | 2024 | 212 | 0.260 |
Why?
|
| Biomarkers | 6 | 2021 | 1407 | 0.260 |
Why?
|
| Hypoglycemic Agents | 1 | 2009 | 220 | 0.260 |
Why?
|
| Empirical Research | 1 | 2006 | 15 | 0.260 |
Why?
|
| Periodicals as Topic | 2 | 2020 | 174 | 0.260 |
Why?
|
| Enterocolitis, Necrotizing | 2 | 2025 | 18 | 0.250 |
Why?
|
| Drug Therapy | 1 | 2006 | 56 | 0.250 |
Why?
|
| Magnetic Resonance Spectroscopy | 4 | 2015 | 294 | 0.250 |
Why?
|
| Anticonvulsants | 1 | 2006 | 104 | 0.240 |
Why?
|
| Health Status | 2 | 2019 | 443 | 0.240 |
Why?
|
| Homeless Youth | 1 | 2005 | 8 | 0.240 |
Why?
|
| Psychoses, Substance-Induced | 1 | 2005 | 5 | 0.230 |
Why?
|
| Double-Blind Method | 10 | 2018 | 738 | 0.230 |
Why?
|
| Mitochondrial Diseases | 1 | 2005 | 22 | 0.230 |
Why?
|
| Health Education | 1 | 2006 | 190 | 0.230 |
Why?
|
| Research Design | 2 | 2018 | 575 | 0.230 |
Why?
|
| Child Behavior | 3 | 2016 | 64 | 0.230 |
Why?
|
| Prevalence | 2 | 2024 | 1387 | 0.220 |
Why?
|
| Image Processing, Computer-Assisted | 5 | 2015 | 659 | 0.210 |
Why?
|
| Pirenzepine | 2 | 2001 | 5 | 0.210 |
Why?
|
| Prefrontal Cortex | 3 | 2015 | 121 | 0.200 |
Why?
|
| Social Adjustment | 3 | 2002 | 36 | 0.200 |
Why?
|
| Depression | 4 | 2025 | 908 | 0.200 |
Why?
|
| Parents | 5 | 2022 | 393 | 0.190 |
Why?
|
| Intestinal Perforation | 1 | 2022 | 17 | 0.190 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2022 | 30 | 0.190 |
Why?
|
| Depressive Disorder | 1 | 2005 | 286 | 0.190 |
Why?
|
| Puberty | 2 | 2005 | 59 | 0.190 |
Why?
|
| Asperger Syndrome | 1 | 2002 | 2 | 0.190 |
Why?
|
| Nerve Growth Factors | 2 | 2019 | 27 | 0.180 |
Why?
|
| Growth and Development | 1 | 2021 | 9 | 0.180 |
Why?
|
| Artificial Intelligence | 1 | 2024 | 182 | 0.180 |
Why?
|
| Retrospective Studies | 7 | 2024 | 6643 | 0.180 |
Why?
|
| Child Nutrition Disorders | 1 | 2021 | 19 | 0.180 |
Why?
|
| Cerebral Intraventricular Hemorrhage | 1 | 2021 | 9 | 0.180 |
Why?
|
| Social Skills | 1 | 2021 | 10 | 0.180 |
Why?
|
| Malnutrition | 1 | 2021 | 41 | 0.170 |
Why?
|
| Leukoencephalopathies | 1 | 2021 | 25 | 0.170 |
Why?
|
| Premature Birth | 1 | 2022 | 112 | 0.170 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2021 | 57 | 0.170 |
Why?
|
| Inflammation | 3 | 2023 | 1147 | 0.170 |
Why?
|
| Functional Laterality | 4 | 2010 | 138 | 0.170 |
Why?
|
| Risk Factors | 6 | 2020 | 5316 | 0.170 |
Why?
|
| Psychomotor Performance | 3 | 2019 | 136 | 0.160 |
Why?
|
| Chorioamnionitis | 1 | 2020 | 14 | 0.160 |
Why?
|
| Databases, Factual | 2 | 2015 | 851 | 0.160 |
Why?
|
| Communication Disorders | 2 | 2013 | 17 | 0.160 |
Why?
|
| Treatment Outcome | 10 | 2018 | 5668 | 0.160 |
Why?
|
| Logistic Models | 4 | 2021 | 1275 | 0.160 |
Why?
|
| Polychlorinated Biphenyls | 1 | 2020 | 40 | 0.160 |
Why?
|
| Academic Performance | 1 | 2019 | 7 | 0.160 |
Why?
|
| Organ Size | 5 | 2019 | 170 | 0.160 |
Why?
|
| Education, Special | 1 | 2019 | 11 | 0.160 |
Why?
|
| Social Behavior | 2 | 2013 | 89 | 0.160 |
Why?
|
| Temperament | 2 | 2014 | 19 | 0.160 |
Why?
|
| Genome-Wide Association Study | 2 | 2019 | 359 | 0.150 |
Why?
|
| Peer Review, Research | 1 | 2020 | 47 | 0.150 |
Why?
|
| Language Disorders | 4 | 2010 | 25 | 0.150 |
Why?
|
| Psychiatry | 1 | 2021 | 126 | 0.150 |
Why?
|
| Environmental Pollutants | 1 | 2020 | 94 | 0.150 |
Why?
|
| Placenta | 1 | 2019 | 61 | 0.150 |
Why?
|
| Patient Dropouts | 1 | 2018 | 49 | 0.150 |
Why?
|
| Racism | 1 | 2020 | 88 | 0.150 |
Why?
|
| Statistics as Topic | 2 | 2011 | 146 | 0.150 |
Why?
|
| Remedial Teaching | 1 | 1998 | 2 | 0.140 |
Why?
|
| Infant Mortality | 1 | 2018 | 20 | 0.140 |
Why?
|
| Hippocampus | 4 | 2015 | 270 | 0.140 |
Why?
|
| Checklist | 2 | 2016 | 73 | 0.140 |
Why?
|
| Linear Models | 4 | 2019 | 409 | 0.140 |
Why?
|
| Conflict of Interest | 1 | 2018 | 37 | 0.140 |
Why?
|
| Disclosure | 1 | 2018 | 56 | 0.140 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2017 | 39 | 0.140 |
Why?
|
| Memory, Short-Term | 1 | 2018 | 60 | 0.140 |
Why?
|
| Epigenomics | 2 | 2019 | 62 | 0.140 |
Why?
|
| Specialization | 1 | 2018 | 80 | 0.140 |
Why?
|
| Multivariate Analysis | 3 | 2024 | 937 | 0.130 |
Why?
|
| Bias | 1 | 2018 | 112 | 0.130 |
Why?
|
| DNA Methylation | 1 | 2019 | 292 | 0.130 |
Why?
|
| Software | 1 | 2020 | 388 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 208 | 0.130 |
Why?
|
| Caudate Nucleus | 3 | 2007 | 25 | 0.130 |
Why?
|
| Putamen | 3 | 2007 | 21 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 222 | 0.130 |
Why?
|
| Physicians | 1 | 2022 | 475 | 0.130 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2016 | 54 | 0.130 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2016 | 29 | 0.130 |
Why?
|
| Cytoskeleton | 1 | 1997 | 139 | 0.130 |
Why?
|
| Erythropoietin | 1 | 2016 | 39 | 0.130 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2016 | 38 | 0.130 |
Why?
|
| Interleukin-8 | 1 | 2016 | 87 | 0.130 |
Why?
|
| Phenotype | 4 | 2023 | 1207 | 0.130 |
Why?
|
| Gray Matter | 1 | 2016 | 36 | 0.120 |
Why?
|
| Apolipoprotein E4 | 1 | 2016 | 46 | 0.120 |
Why?
|
| Surveys and Questionnaires | 5 | 2023 | 2703 | 0.120 |
Why?
|
| Serotonin 5-HT1 Receptor Agonists | 1 | 2015 | 5 | 0.120 |
Why?
|
| Students | 1 | 1998 | 220 | 0.120 |
Why?
|
| Actins | 1 | 1997 | 259 | 0.120 |
Why?
|
| Internal-External Control | 1 | 2015 | 34 | 0.120 |
Why?
|
| Behavior Rating Scale | 1 | 2015 | 2 | 0.120 |
Why?
|
| C-Reactive Protein | 1 | 2016 | 166 | 0.120 |
Why?
|
| Breast Neoplasms | 1 | 2024 | 1208 | 0.120 |
Why?
|
| Psychology, Child | 1 | 2015 | 7 | 0.120 |
Why?
|
| Genetics | 1 | 2015 | 13 | 0.120 |
Why?
|
| Psychology, Adolescent | 1 | 2015 | 27 | 0.120 |
Why?
|
| Cholecalciferol | 1 | 2015 | 28 | 0.110 |
Why?
|
| Pregnancy Complications | 3 | 2015 | 378 | 0.110 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2016 | 212 | 0.110 |
Why?
|
| Psychometrics | 4 | 2023 | 384 | 0.110 |
Why?
|
| Creatinine | 1 | 2015 | 134 | 0.110 |
Why?
|
| Valproic Acid | 2 | 2006 | 24 | 0.110 |
Why?
|
| Brief Psychiatric Rating Scale | 2 | 2007 | 13 | 0.110 |
Why?
|
| Aripiprazole | 1 | 2014 | 5 | 0.110 |
Why?
|
| Prodromal Symptoms | 1 | 2014 | 18 | 0.110 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2015 | 154 | 0.110 |
Why?
|
| Income | 1 | 2015 | 170 | 0.110 |
Why?
|
| Temporal Lobe | 2 | 2009 | 45 | 0.110 |
Why?
|
| Anger | 1 | 2014 | 22 | 0.110 |
Why?
|
| Educational Status | 1 | 2015 | 278 | 0.100 |
Why?
|
| Evidence-Based Medicine | 2 | 2013 | 462 | 0.100 |
Why?
|
| Psychopathology | 1 | 2013 | 22 | 0.100 |
Why?
|
| Parental Death | 1 | 2013 | 3 | 0.100 |
Why?
|
| Haloperidol | 5 | 1997 | 16 | 0.100 |
Why?
|
| Hallucinations | 1 | 2013 | 16 | 0.100 |
Why?
|
| Ambulatory Care | 2 | 2006 | 311 | 0.100 |
Why?
|
| Oxytocics | 1 | 2013 | 14 | 0.100 |
Why?
|
| Bullying | 1 | 2013 | 16 | 0.100 |
Why?
|
| Functional Neuroimaging | 1 | 2013 | 15 | 0.100 |
Why?
|
| Psychotherapy | 2 | 2021 | 99 | 0.100 |
Why?
|
| Methylphenidate | 1 | 2013 | 19 | 0.100 |
Why?
|
| Cerebellum | 2 | 2013 | 95 | 0.100 |
Why?
|
| Disorders of Excessive Somnolence | 3 | 2002 | 16 | 0.100 |
Why?
|
| Comprehension | 3 | 2024 | 139 | 0.100 |
Why?
|
| Globus Pallidus | 2 | 2007 | 26 | 0.100 |
Why?
|
| Dietary Supplements | 1 | 2015 | 235 | 0.100 |
Why?
|
| Central Nervous System Stimulants | 1 | 2013 | 64 | 0.100 |
Why?
|
| Database Management Systems | 1 | 2012 | 19 | 0.090 |
Why?
|
| Motion Perception | 1 | 2012 | 5 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2013 | 775 | 0.090 |
Why?
|
| Mothers | 1 | 2015 | 276 | 0.090 |
Why?
|
| Information Systems | 1 | 2012 | 29 | 0.090 |
Why?
|
| Norway | 3 | 2016 | 23 | 0.090 |
Why?
|
| Diagnosis, Differential | 2 | 2013 | 981 | 0.090 |
Why?
|
| Glutamic Acid | 2 | 2015 | 99 | 0.090 |
Why?
|
| Socioeconomic Factors | 3 | 2024 | 784 | 0.090 |
Why?
|
| Proteins | 1 | 1997 | 750 | 0.090 |
Why?
|
| Health Resources | 1 | 2012 | 95 | 0.090 |
Why?
|
| Analysis of Variance | 6 | 2012 | 609 | 0.090 |
Why?
|
| Social Class | 2 | 2024 | 136 | 0.090 |
Why?
|
| Anatomy, Cross-Sectional | 1 | 2010 | 8 | 0.090 |
Why?
|
| Dominance, Cerebral | 1 | 2010 | 33 | 0.090 |
Why?
|
| Mass Screening | 1 | 2016 | 694 | 0.080 |
Why?
|
| Myelin Sheath | 1 | 2010 | 37 | 0.080 |
Why?
|
| Aggression | 2 | 2014 | 64 | 0.080 |
Why?
|
| Smoking | 1 | 2015 | 866 | 0.080 |
Why?
|
| Time Factors | 5 | 2013 | 3731 | 0.080 |
Why?
|
| Vitamins | 1 | 2011 | 80 | 0.080 |
Why?
|
| Regression Analysis | 2 | 2015 | 498 | 0.080 |
Why?
|
| Chronic Disease | 3 | 2015 | 753 | 0.080 |
Why?
|
| Energy Metabolism | 1 | 2013 | 380 | 0.080 |
Why?
|
| Frontal Lobe | 2 | 2013 | 64 | 0.080 |
Why?
|
| Models, Biological | 2 | 2017 | 1181 | 0.080 |
Why?
|
| Data Interpretation, Statistical | 1 | 2010 | 194 | 0.080 |
Why?
|
| Intensive Care Units, Neonatal | 2 | 2022 | 82 | 0.080 |
Why?
|
| Vitamin D | 1 | 2011 | 140 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 455 | 0.080 |
Why?
|
| Waist Circumference | 1 | 2009 | 45 | 0.080 |
Why?
|
| Facial Expression | 1 | 2009 | 16 | 0.080 |
Why?
|
| Infant, Premature | 2 | 2022 | 185 | 0.080 |
Why?
|
| Obesity | 2 | 2022 | 1235 | 0.080 |
Why?
|
| Genetic Testing | 1 | 2010 | 134 | 0.080 |
Why?
|
| Genotype | 3 | 2016 | 662 | 0.070 |
Why?
|
| Amygdala | 2 | 2007 | 83 | 0.070 |
Why?
|
| Language | 1 | 2010 | 150 | 0.070 |
Why?
|
| Internet | 1 | 2012 | 469 | 0.070 |
Why?
|
| Cross-Sectional Studies | 3 | 2025 | 2586 | 0.070 |
Why?
|
| Cerebral Ventricles | 3 | 1996 | 29 | 0.070 |
Why?
|
| Antidepressive Agents | 2 | 2006 | 226 | 0.070 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2010 | 286 | 0.070 |
Why?
|
| Triglycerides | 1 | 2009 | 245 | 0.070 |
Why?
|
| Occipital Lobe | 1 | 2007 | 17 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2017 | 864 | 0.070 |
Why?
|
| Carbamazepine | 1 | 2006 | 10 | 0.060 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2006 | 9 | 0.060 |
Why?
|
| Nucleus Accumbens | 1 | 2007 | 45 | 0.060 |
Why?
|
| Integration Host Factors | 1 | 2006 | 2 | 0.060 |
Why?
|
| Triazines | 1 | 2006 | 17 | 0.060 |
Why?
|
| Forecasting | 1 | 2008 | 233 | 0.060 |
Why?
|
| Feasibility Studies | 3 | 2017 | 571 | 0.060 |
Why?
|
| Weight Loss | 1 | 2009 | 274 | 0.060 |
Why?
|
| Amines | 1 | 2006 | 30 | 0.060 |
Why?
|
| Blood Glucose | 1 | 2009 | 484 | 0.060 |
Why?
|
| Psychology | 1 | 2006 | 45 | 0.060 |
Why?
|
| Protons | 2 | 2022 | 62 | 0.060 |
Why?
|
| Child Reactive Disorders | 1 | 2006 | 1 | 0.060 |
Why?
|
| Treatment Refusal | 1 | 2006 | 56 | 0.060 |
Why?
|
| Fructose | 1 | 2006 | 38 | 0.060 |
Why?
|
| Body Weight | 3 | 2017 | 379 | 0.060 |
Why?
|
| Pilot Projects | 3 | 2022 | 1016 | 0.060 |
Why?
|
| Hospitalization | 2 | 2021 | 1361 | 0.060 |
Why?
|
| Combined Modality Therapy | 1 | 2006 | 375 | 0.060 |
Why?
|
| Telencephalon | 1 | 2005 | 10 | 0.060 |
Why?
|
| Epilepsy, Tonic-Clonic | 1 | 2005 | 8 | 0.060 |
Why?
|
| Blindness | 1 | 2025 | 42 | 0.060 |
Why?
|
| Insulin | 1 | 2009 | 686 | 0.060 |
Why?
|
| Body Mass Index | 1 | 2009 | 869 | 0.060 |
Why?
|
| Adolescent Health | 1 | 2025 | 14 | 0.060 |
Why?
|
| Hospitals, Psychiatric | 1 | 2005 | 56 | 0.060 |
Why?
|
| Sexuality | 2 | 2002 | 25 | 0.060 |
Why?
|
| Reaction Time | 4 | 1999 | 125 | 0.060 |
Why?
|
| Atrophy | 1 | 2005 | 83 | 0.060 |
Why?
|
| Hospitals, Pediatric | 1 | 2005 | 52 | 0.060 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2025 | 32 | 0.060 |
Why?
|
| Obsessive-Compulsive Disorder | 2 | 2002 | 36 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2005 | 1121 | 0.050 |
Why?
|
| Peer Group | 1 | 2025 | 105 | 0.050 |
Why?
|
| Maternal Age | 1 | 2024 | 33 | 0.050 |
Why?
|
| Maternal Health | 1 | 2024 | 15 | 0.050 |
Why?
|
| Sex Ratio | 1 | 2004 | 8 | 0.050 |
Why?
|
| Health Literacy | 1 | 2024 | 85 | 0.050 |
Why?
|
| Biotransformation | 1 | 2003 | 23 | 0.050 |
Why?
|
| Character | 1 | 2003 | 2 | 0.050 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2003 | 47 | 0.050 |
Why?
|
| Area Under Curve | 1 | 2003 | 147 | 0.050 |
Why?
|
| Hair Follicle | 1 | 2022 | 34 | 0.050 |
Why?
|
| Pursuit, Smooth | 3 | 1996 | 3 | 0.050 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2003 | 230 | 0.050 |
Why?
|
| Self Report | 2 | 2015 | 381 | 0.050 |
Why?
|
| Fragile X Mental Retardation Protein | 1 | 2022 | 38 | 0.050 |
Why?
|
| Task Performance and Analysis | 1 | 2023 | 129 | 0.050 |
Why?
|
| Biological Phenomena | 1 | 2002 | 4 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 731 | 0.050 |
Why?
|
| Nerve Fibers, Myelinated | 2 | 2012 | 30 | 0.050 |
Why?
|
| Echoencephalography | 1 | 2021 | 13 | 0.040 |
Why?
|
| Probability | 1 | 2021 | 170 | 0.040 |
Why?
|
| Interdisciplinary Research | 1 | 2021 | 4 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 2003 | 202 | 0.040 |
Why?
|
| India | 1 | 2021 | 159 | 0.040 |
Why?
|
| Appetite | 1 | 2001 | 16 | 0.040 |
Why?
|
| Academies and Institutes | 1 | 2020 | 24 | 0.040 |
Why?
|
| Neural Pathways | 2 | 2012 | 99 | 0.040 |
Why?
|
| Patient Education as Topic | 1 | 2024 | 477 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2005 | 723 | 0.040 |
Why?
|
| Halogenated Diphenyl Ethers | 1 | 2020 | 9 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2002 | 467 | 0.040 |
Why?
|
| Tics | 1 | 2000 | 7 | 0.040 |
Why?
|
| Psychosocial Support Systems | 1 | 2020 | 12 | 0.040 |
Why?
|
| Tourette Syndrome | 1 | 2000 | 15 | 0.040 |
Why?
|
| Organophosphorus Compounds | 1 | 2020 | 31 | 0.040 |
Why?
|
| Abdominal Pain | 1 | 2001 | 102 | 0.040 |
Why?
|
| Middle Aged | 5 | 2022 | 17678 | 0.040 |
Why?
|
| Domestic Violence | 1 | 2020 | 39 | 0.040 |
Why?
|
| Social Isolation | 1 | 2020 | 36 | 0.040 |
Why?
|
| Research | 1 | 2021 | 195 | 0.040 |
Why?
|
| Reference Values | 2 | 2015 | 331 | 0.040 |
Why?
|
| Nervous System Diseases | 1 | 2001 | 107 | 0.040 |
Why?
|
| Caregivers | 1 | 2022 | 277 | 0.040 |
Why?
|
| Parturition | 1 | 2019 | 55 | 0.040 |
Why?
|
| Blood Proteins | 1 | 2019 | 76 | 0.040 |
Why?
|
| Angiopoietin-1 | 1 | 2018 | 2 | 0.040 |
Why?
|
| Family | 1 | 2020 | 242 | 0.040 |
Why?
|
| Chemokine CCL5 | 1 | 2018 | 33 | 0.040 |
Why?
|
| Hearing Disorders | 1 | 2018 | 10 | 0.040 |
Why?
|
| Prognosis | 2 | 2018 | 1744 | 0.040 |
Why?
|
| Patient Compliance | 1 | 2001 | 360 | 0.040 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2018 | 35 | 0.040 |
Why?
|
| Seizures | 2 | 2016 | 143 | 0.040 |
Why?
|
| Environmental Exposure | 1 | 2020 | 218 | 0.040 |
Why?
|
| Mathematics | 1 | 1998 | 34 | 0.040 |
Why?
|
| CpG Islands | 1 | 2019 | 216 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2022 | 5481 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 181 | 0.040 |
Why?
|
| Vision Disorders | 1 | 2018 | 65 | 0.030 |
Why?
|
| Executive Function | 1 | 2018 | 65 | 0.030 |
Why?
|
| Galvanic Skin Response | 1 | 1997 | 24 | 0.030 |
Why?
|
| Language Tests | 2 | 2010 | 39 | 0.030 |
Why?
|
| Critical Care | 1 | 2021 | 397 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2016 | 1093 | 0.030 |
Why?
|
| Office Visits | 1 | 2017 | 48 | 0.030 |
Why?
|
| Agenesis of Corpus Callosum | 1 | 1997 | 6 | 0.030 |
Why?
|
| Homovanillic Acid | 1 | 1997 | 6 | 0.030 |
Why?
|
| Methoxyhydroxyphenylglycol | 1 | 1997 | 9 | 0.030 |
Why?
|
| Hydroxyindoleacetic Acid | 1 | 1997 | 11 | 0.030 |
Why?
|
| Blinking | 1 | 1996 | 4 | 0.030 |
Why?
|
| Menarche | 1 | 1997 | 37 | 0.030 |
Why?
|
| Metabolic Clearance Rate | 1 | 2017 | 49 | 0.030 |
Why?
|
| Conserved Sequence | 1 | 1997 | 173 | 0.030 |
Why?
|
| Reading | 1 | 1998 | 92 | 0.030 |
Why?
|
| Survivors | 1 | 2018 | 178 | 0.030 |
Why?
|
| Half-Life | 1 | 2017 | 80 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 1998 | 141 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2022 | 1536 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2017 | 87 | 0.030 |
Why?
|
| Attention | 1 | 1998 | 147 | 0.030 |
Why?
|
| Anisotropy | 1 | 2016 | 61 | 0.030 |
Why?
|
| Self-Help Devices | 1 | 2016 | 5 | 0.030 |
Why?
|
| Microcephaly | 1 | 2016 | 14 | 0.030 |
Why?
|
| Communication | 1 | 2021 | 580 | 0.030 |
Why?
|
| Heart Rate | 1 | 1997 | 322 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2019 | 385 | 0.030 |
Why?
|
| Mobility Limitation | 1 | 2016 | 49 | 0.030 |
Why?
|
| Program Evaluation | 1 | 1998 | 488 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 316 | 0.030 |
Why?
|
| Prolactin | 2 | 2010 | 40 | 0.030 |
Why?
|
| Psychological Tests | 1 | 2015 | 46 | 0.030 |
Why?
|
| Anthropometry | 1 | 2015 | 84 | 0.030 |
Why?
|
| Propensity Score | 1 | 2015 | 160 | 0.030 |
Why?
|
| Binding Sites | 1 | 1997 | 906 | 0.030 |
Why?
|
| Multimodal Imaging | 1 | 2015 | 69 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2023 | 1105 | 0.030 |
Why?
|
| Models, Neurological | 1 | 2015 | 79 | 0.030 |
Why?
|
| Glucose | 1 | 1997 | 467 | 0.030 |
Why?
|
| Affect | 1 | 2015 | 127 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-fyn | 1 | 2014 | 6 | 0.030 |
Why?
|
| Interview, Psychological | 1 | 2014 | 79 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2014 | 17 | 0.030 |
Why?
|
| Hostility | 1 | 2014 | 17 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 1997 | 1591 | 0.030 |
Why?
|
| Curriculum | 1 | 1998 | 602 | 0.030 |
Why?
|
| Mental Recall | 1 | 2014 | 93 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 1997 | 1992 | 0.030 |
Why?
|
| Asthma | 1 | 2018 | 466 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2018 | 1010 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 1152 | 0.030 |
Why?
|
| Phosphocreatine | 1 | 2013 | 25 | 0.020 |
Why?
|
| Poverty | 1 | 2015 | 298 | 0.020 |
Why?
|
| Remission Induction | 1 | 2013 | 148 | 0.020 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2013 | 113 | 0.020 |
Why?
|
| Calcium Signaling | 1 | 2014 | 157 | 0.020 |
Why?
|
| Patient Selection | 1 | 2015 | 491 | 0.020 |
Why?
|
| Phosphates | 1 | 2013 | 93 | 0.020 |
Why?
|
| Software Design | 1 | 2012 | 28 | 0.020 |
Why?
|
| Aged | 2 | 2022 | 14477 | 0.020 |
Why?
|
| Intelligence Tests | 1 | 2012 | 26 | 0.020 |
Why?
|
| Speech Disorders | 2 | 2006 | 17 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2012 | 77 | 0.020 |
Why?
|
| Photic Stimulation | 1 | 2012 | 90 | 0.020 |
Why?
|
| User-Computer Interface | 1 | 2012 | 125 | 0.020 |
Why?
|
| Species Specificity | 1 | 2012 | 334 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2013 | 458 | 0.020 |
Why?
|
| Homeostasis | 1 | 2014 | 368 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2018 | 2045 | 0.020 |
Why?
|
| Observer Variation | 2 | 2005 | 215 | 0.020 |
Why?
|
| Nonlinear Dynamics | 1 | 2010 | 25 | 0.020 |
Why?
|
| Akathisia, Drug-Induced | 1 | 2010 | 5 | 0.020 |
Why?
|
| Rats, Long-Evans | 1 | 2010 | 22 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2010 | 110 | 0.020 |
Why?
|
| Karyotyping | 1 | 2010 | 47 | 0.020 |
Why?
|
| Cerebellar Cortex | 1 | 2010 | 10 | 0.020 |
Why?
|
| DNA | 1 | 2015 | 838 | 0.020 |
Why?
|
| Rest | 1 | 2010 | 46 | 0.020 |
Why?
|
| Consciousness | 1 | 2010 | 12 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2010 | 64 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2010 | 292 | 0.020 |
Why?
|
| Wakefulness | 1 | 2010 | 43 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 2010 | 121 | 0.020 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2010 | 98 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2010 | 370 | 0.020 |
Why?
|
| Long-Term Care | 1 | 2010 | 177 | 0.020 |
Why?
|
| Cerebrovascular Circulation | 1 | 2010 | 181 | 0.020 |
Why?
|
| Oxygen | 1 | 2010 | 317 | 0.020 |
Why?
|
| Rats | 1 | 2010 | 1982 | 0.020 |
Why?
|
| Sertraline | 1 | 2006 | 58 | 0.020 |
Why?
|
| Body Height | 1 | 2006 | 66 | 0.020 |
Why?
|
| Animals | 2 | 2010 | 20696 | 0.020 |
Why?
|
| Drug Resistance | 1 | 2007 | 153 | 0.020 |
Why?
|
| Faculty | 1 | 2006 | 53 | 0.020 |
Why?
|
| Streptococcal Infections | 1 | 2006 | 80 | 0.010 |
Why?
|
| Missouri | 1 | 2005 | 10 | 0.010 |
Why?
|
| Drug Administration Schedule | 2 | 1996 | 299 | 0.010 |
Why?
|
| Physicians, Family | 1 | 2005 | 75 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2014 | 3031 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 2006 | 474 | 0.010 |
Why?
|
| Boston | 1 | 2002 | 250 | 0.010 |
Why?
|
| Neurologic Examination | 1 | 2001 | 53 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2006 | 791 | 0.010 |
Why?
|
| Patient Admission | 1 | 2000 | 198 | 0.010 |
Why?
|
| Habituation, Psychophysiologic | 1 | 1997 | 4 | 0.010 |
Why?
|
| Tomography, Emission-Computed | 1 | 1997 | 42 | 0.010 |
Why?
|
| Autonomic Nervous System | 1 | 1997 | 36 | 0.010 |
Why?
|
| Orientation | 1 | 1997 | 26 | 0.010 |
Why?
|
| Syndrome | 1 | 1998 | 180 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 1998 | 418 | 0.010 |
Why?
|
| Neurotransmitter Agents | 1 | 1997 | 42 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 1997 | 189 | 0.010 |
Why?
|
| Neutropenia | 1 | 1996 | 67 | 0.010 |
Why?
|
| Eye Movements | 1 | 1996 | 83 | 0.010 |
Why?
|
| Adolescent Behavior | 1 | 1996 | 194 | 0.010 |
Why?
|
| National Institute of Mental Health (U.S.) | 1 | 1994 | 3 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 1994 | 265 | 0.010 |
Why?
|